An observational study in Mitochondrial Diseases, Myalgic Encephalomyelitis Chronic Fatigue Syndrome and Post-COVID-19 Condition, sponsored by AI Agent Vault, Inc. d/b/a Precision Mito. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by AI Agent Vault, Inc. d/b/a Precision Mito · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Mitochondrial Diseases with a site in United States — 20 open to participants now, 22 under way, 3 of them phase 3. Mitochondrial Diseases · United States.
Among the 83 studies in Mitochondrial Diseases with a site in United States, this one is the 8th largest by planned enrollment of the 31 observational ones that give a count, is one of 4 that started in 2026, is one of 31 observational ones, reaches primary completion later than 17 of the 21 other live ones, and was the 82nd registered.
189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.
Browse Mitochondrial Diseases studies →20 of the 83 studies in Mitochondrial Diseases with a site in United States are open now. Recruiting first, the newest first:
Pharming Technologies B.V. · Sites in United States, Belgium, Czechia and 6 more countries
Ages 18+
Khondrion BV · Sites in United States, Denmark, France and 4 more countries
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 8–75 · Healthy volunteers
Children's Hospital of Philadelphia · Sites in United States
Ages 18–65 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Mitochondrial Diseases studies recruiting now, 20 (49%) set no upper age limit and 14 (34%) stop at 75 or younger; 19 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 21 · Phase 3 11 · Phase 4 3
First in 2000; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 80 across 65 observational studies indexed under Mitochondrial Diseases.
Median enrollment 38 across the 50 interventional studies, 61 across the 31 observational. Of the 54 that completed or were terminated, 23 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 83 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with AI Agent Vault, Inc. d/b/a Precision Mito as lead sponsor.
AI Agent Vault, Inc. d/b/a Precision Mito has 1 study filed under Mitochondrial Diseases — fewer than ten, so there is no comparison to draw.
9 of the studies in Mitochondrial Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
| NCT01803906Columbia UniversityTissue Sample Study for Mitochondrial Disorders | 2026-12 |
| NCT02000284University of ArkansasMitochondrial Dysfunction in Autism Spectrum Disorder | 2026-12-31 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
| NCT03639701Columbia UniversityTreatment of TK2 Deficiency With Thymidine and Deoxycytidine | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 83 studies in Mitochondrial Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Mito Map is a research tool that produces an Energy Score from information provided by a participant. This remote observational study has an initial enrollment target of 400 adults across seven prespecified cohorts: healthy comparison participants; broad mitochondrial disease; POLG-related disease; post-infectious or autonomic illness; Lyme disease or post-treatment Lyme disease syndrome; cancer or cancer-survivorship related fatigue; and other neuromuscular or persistent energy-limiting conditions. The broad mitochondrial cohort has an initial target of 100 participants, and each other cohort has an initial target of 50 participants. These are planning targets rather than caps.
Participants complete a baseline assessment and repeated assessments about every two weeks for 12 weeks. Routine activity is designed to take about 5-10 minutes per week, although screening, consent, baseline setup, troubleshooting, or safety follow-up may take longer. Assessments include the Energy Score and protocolized home measures of physical function such as grip strength and five-times sit-to-stand performance, with an approved alternative when grip testing is unsuitable. Participants assigned to grip testing receive a study-provided hand-grip dynamometer at no cost. Optional compatible wearable data may be collected continuously when authorized and technically available.
The study does not assign treatment, and research scores will not be used to make clinical decisions. The primary hypothesis is that, within the same participant, higher-than-usual Energy Score values will be associated with better-than-usual objective functional performance at matched assessments. Cohort comparisons, including POLG-specific analyses, are exploratory. A separately consented subset may use a study-provided Flic button to create timestamped symptom, context, or intervention markers with optional follow-up confirmation. The device module is not continuously monitored, does not assign treatment, and is not an emergency service.
COMPASS is a prospective, remote, longitudinal observational cohort study designed to externally evaluate the measurement behavior and longitudinal criterion validity of the frozen canonical Mito Map Energy Score. Participants complete seven matched assessments from baseline through week 12.
The primary objective is to estimate the average within-person association between changes in the Energy Score and changes in a separately constructed objective home-function anchor based on protocolized grip-strength and five-times sit-to-stand measurements. The primary anchor excludes fatigue and shares no inputs with the Energy Score.
The initial enrollment target is 400 adults across seven prespecified cohorts: healthy comparison; broad mitochondrial disease; POLG-related disease; post-infectious or autonomic illness; cancer and cancer survivorship; other persistent energy-limiting conditions; and Lyme disease or post-treatment Lyme disease syndrome. Participants meeting the dedicated POLG cohort definition are assigned to that cohort rather than the broad mitochondrial cohort. The 50-person POLG cohort is prespecified for descriptive and exploratory subgroup analyses and is not separately powered for confirmatory POLG-specific, variant-level, prognostic, or treatment-response claims.
Secondary objectives include characterizing between-person association, test-retest reliability, adherence, missingness, assessment failures, participant burden, and safety during home measurement. Exploratory analyses will examine prediction of the next functional assessment, longitudinal transition yield, naturally occurring exposure changes, optional wearable measures, optional Flic symptom, context, and confirmed intervention markers, and variation across the seven cohorts. Cohort comparisons are exploratory and are intended to help distinguish shared and condition-specific patterns across complex energy-limiting illnesses.
The study is non-interventional. It does not assign medications, supplements, devices, exercise, diet, or other treatment. Results will not establish diagnosis, treatment efficacy, clinical utility, prognosis, mitochondrial ATP production, or a minimum clinically important difference. The same dataset will not be used both to tune the Energy Score or functional anchor and to claim locked external validation.
Community-dwelling adults who volunteer through approved digital outreach, disease-community or nonprofit outreach, an existing research-interest list, or authorized clinician and research-partner referrals. Participants must reside in an approved jurisdiction and qualify for one of seven prespecified cohorts. The anticipated enrollment is 400: 100 in the broad mitochondrial cohort and 50 in each of the other six cohorts, including the dedicated POLG cohort. These are planning targets rather than enrollment caps.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants meeting the dedicated POLG cohort definition are assigned to that cohort rather than the broad mitochondrial cohort. Final eligibility and cohort assignment are determined by qualified study personnel. Software may collect and flag screening information but does not make the final enrollment decision.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults without a diagnosed or suspected mitochondrial disorder, active cancer, Lyme disease, or a persistent energy-limiting condition. Participants complete the same schedule and safety screening as the patient cohorts.
Other: Mito Map Energy Score and Home Functional Assessments
Adults with confirmed or suspected primary mitochondrial disease or clinically documented mitochondrial dysfunction who do not meet the dedicated POLG cohort definition. Participants meeting the POLG cohort definition are assigned to the dedicated POLG cohort rather than this broad mitochondrial cohort. Diagnostic certainty, genetic findings, syndrome, phenotype, and severity are recorded without representing suspected disease as genetically confirmed disease.
Other: Mito Map Energy Score and Home Functional Assessments
Adults with ME/CFS, Long COVID, POTS or dysautonomia, or a related post-infectious or autonomic energy-limiting illness. Lyme disease participants whose current index condition is Lyme-related are assigned to the separate Lyme cohort.
Other: Mito Map Energy Score and Home Functional Assessments
Adults with active cancer, a history of cancer, or treatment-related fatigue for whom remote functional testing is appropriate. Disease status, treatment status, time since treatment, and major fatigue confounders are recorded.
Other: Mito Map Energy Score and Home Functional Assessments
Adults with neuromuscular disease, fibromyalgia, complex chronic illness, or another qualifying persistent energy-limiting condition that is not assigned to another predefined cohort.
Other: Mito Map Energy Score and Home Functional Assessments
Adults with clinician-diagnosed Lyme disease, including persistent symptoms following recommended treatment when documented. Diagnostic basis, treatment history, time since treatment, symptom duration, coinfections, and alternative explanations are recorded. Enrollment does not imply persistent infection.
Other: Mito Map Energy Score and Home Functional Assessments
Adults with confirmed or suspected POLG-related disease based on documented genetic findings or a specialist clinical diagnosis. Participants meeting this dedicated cohort definition are assigned here rather than to the broad mitochondrial cohort. Genetic findings, variant classification, zygosity, phenotype, diagnostic certainty, and disease severity are recorded without representing suspected disease or uncertain variants as genetically confirmed disease. This 50-person planning cohort is intended for descriptive and exploratory analyses and is not separately powered for confirmatory POLG-specific, variant-level, prognostic, or treatment-response claims.
Other: Mito Map Energy Score and Home Functional Assessments
Observational measurement package completed at baseline and approximately every two weeks through week 12. It includes the canonical Mito Map Energy Score and protocolized home measures of objective function, including grip strength and five-times sit-to-stand when safe and feasible. Participants are not assigned treatment, and these measurements are not used for diagnosis or clinical decision-making.
Within-participant association between canonical Energy Score and objective home function composite
Coefficient for within-person centered canonical Energy Score in a participant fixed-effects model of the participant-self-administered, unblinded objective home function composite, adjusted for centered elapsed week and locked measurement-condition covariates, with participant-cluster-robust sandwich standard errors. The anchor is algorithmically independent because it shares no inputs with the Energy Score; it is not independently administered or blinded.
Time frame: Baseline through week 12
Within-participant association between canonical Energy Score and full Measured Function Score
Fixed-effect coefficient for within-person centered canonical Energy Score in the longitudinal model of the locked Measured Function Score that includes fatigue. Interpretation will explicitly acknowledge shared symptom inputs and possible circularity.
Time frame: Baseline through week 12
Within-participant association between canonical Energy Score and grip strength
Fixed-effect coefficient for within-person centered canonical Energy Score in the longitudinal model of maximum valid grip force from three protocolized attempts. Grip force is natural-log transformed; device, hand, and measurement-condition covariates are recorded.
Time frame: Baseline through week 12
Within-participant association between canonical Energy Score and five-times sit-to-stand performance
Fixed-effect coefficient for within-person centered canonical Energy Score in the longitudinal model of natural-log five-times-sit-to-stand seconds, direction aligned so higher values indicate better performance.
Time frame: Baseline through week 12
Energy Score test-retest reliability during clinically stable intervals
Absolute-agreement single-measure ICC(A,1) from a two-way mixed-effects model and standard error of measurement for adjacent assessments with no acute infection, hospitalization or urgent visit, function-altering medication change in the prior 7 days, unusual exertion in the prior 48 hours, or major measurement-protocol deviation.
Time frame: Adjacent assessments from baseline through week 12
Assessment completion
Number and percentage of seven scheduled assessments completed with usable matched canonical Energy Score and objective functional data. Reasons for missing or unusable assessments will be summarized.
Time frame: Baseline and Weeks 2, 4, 6, 8, 10, and 12
Adverse events during home measurement
Counts and percentages of participants with adverse events and serious adverse events temporally associated with study measurement procedures, summarized by event type, severity, relatedness, and action taken.
Time frame: From informed consent through participant closeout after the Week 12 assessment (approximately 12 weeks of scheduled follow-up from baseline).
Between-participant association between mean Energy Score and mean objective home function
Association between each participant's mean canonical Energy Score and mean objective home function composite, reported separately from the primary within-person estimand.
Time frame: Baseline through week 12
Incremental prediction of the next objective functional assessment
Difference in root mean squared prediction error under participant-grouped 10-fold cross-validation between a model containing current objective function and elapsed time and a model that additionally contains current canonical Energy Score. This exploratory analysis does not establish prognosis or clinical utility.
Time frame: Weeks 2 through 12
Variation in the primary association across prespecified cohorts
Energy Score-by-cohort interaction estimates and cohort-specific coefficients with confidence intervals. The study is not powered for interaction detection; results are exploratory, and absence of significance will not be interpreted as equivalence between cohorts.
Time frame: Baseline through week 12
Quality-qualified longitudinal transition yield
Number and percentage of up to six adjacent scheduled assessment intervals per participant that qualify. Both assessments must occur within the prespecified visit windows and contain the canonical Energy Score, objective functional anchor, timestamps, and required completeness fields. Qualification describes analyzable longitudinal coverage and does not imply clinical change or causality.
Time frame: Adjacent scheduled assessments from baseline through week 12
Longitudinal transition depth
Median and distribution of quality-qualified adjacent scheduled intervals per participant, plus the percentage of participants with at least four qualified intervals. Reasons for nonqualification will be summarized by prespecified category.
Time frame: Baseline through week 12
Naturally occurring exposure-linked transition yield
Number and percentage of quality-qualified adjacent scheduled intervals containing a prospectively recorded participant-initiated, clinically directed, or otherwise naturally occurring change in a prespecified exposure category. The study assigns no treatment and does not interpret this measure as a causal treatment effect.
Time frame: Adjacent scheduled assessments from baseline through week 12
Optional Flic symptom-event capture feasibility
Among participants consenting to the optional Flic module: activated devices; active participant-weeks; event count and event days per participant-week; percentage of events received within 24 hours; and delayed, duplicate, unmapped, test, corrected, and failed-event rates. No minimum event count is required because absence of a press cannot be interpreted as absence of symptoms.
Time frame: From optional-module activation through week 12
Optional Flic confirmed intervention-marker yield
Among Flic events mapped to an intervention: number and percentage followed by participant confirmation of intervention identity, occurrence, timing, and required exposure details; time to confirmation; and number linked to a quality-qualified adjacent assessment interval. Unconfirmed markers are not counted as intervention exposures, adherence, or perturbation-linked transitions.
Time frame: From optional-module activation through week 12
Optional Flic symptom-annotation completion
Percentage of eligible Flic events with a completed requested follow-up annotation, median time from event to annotation, and distribution of participant-selected symptom or context labels. Analyses are descriptive and do not treat button events as validated symptom severity or clinical outcomes.
Time frame: From optional-module activation through week 12
Plan to share: Yes — Coded or de-identified participant-level data underlying approved analyses may be shared together with an approved data dictionary, protocol, statistical analysis plan, and analytic code when available. Direct identifiers are not included unless separately and specifically authorized and legally permitted.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Sharing may begin after completion of the primary analysis and disclosure review. Availability duration will follow the final retention and commercial-data-use terms stated in the approved consent and governing agreements.
Access criteria: Access may be provided to qualified academic, nonprofit, governmental, pharmaceutical, biotechnology, diagnostic, medical-device, digital-health, data, or other commercial recipients, including independent analysts, research organizations, and publication collaborators, for permitted research, analysis, interpretation, regulatory, publication, product-development, or commercialization purposes. Access requires sponsor review and an appropriate written agreement containing use, security, confidentiality, onward-transfer, re-identification, conflict-disclosure, and publication provisions. Controlled access, license, or transfer will be administered by the sponsor or its authorized data-governance service. No public participant-level download is promised.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.
Of 33 observational studies under Mitochondrial Diseases, half reached primary completion within 169 months of starting (the median), counting those still running; a quarter within 26. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.